Faron Pharmaceuticals: Blood cancer study BEXMAB in full swing

Faron has prepared for increased bexmarilimab production and accelerated its BEXMAB study, which resulted in higher R&D costs and a weaker result than we expected. Our estimate changes are marginal, as we recently updated our assessment of the progress of the drug development program. The valuation picture remains unchanged compared to our assessment in January, as there have been no major changes in the timing or financial outlook of the studies.